Renal Denervation Devices - Global Strategic Business Report

The global market for Renal Denervation Devices was valued at US$1.1 Billion in 2024 and is projected to reach US$2.2 Billion by 2030, growing at a CAGR of 13.1% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Renal Denervation Devices market.

Global “Renal Denervation Devices” Market - Key Trends & Drivers Summarized

Why Are Renal Denervation Devices Being Hailed as a Breakthrough in Hypertension Management?

Renal denervation (RDN) devices are poised to revolutionize the treatment of drug-resistant hypertension, one of the most prevalent and persistent health challenges worldwide. These devices use radiofrequency, ultrasound, or chemical ablation to disrupt overactive renal sympathetic nerves - nerves that contribute significantly to elevated blood pressure. Despite multiple pharmacological options, many patients struggle to achieve target blood pressure levels due to poor medication adherence or ineffectiveness of drug therapy. RDN provides a minimally invasive, long-lasting solution, particularly appealing to patients and physicians seeking alternatives to lifelong drug regimens. As hypertension remains a leading cause of cardiovascular disease and mortality globally, the clinical relevance and market potential for RDN devices are substantial.

How Are Clinical Trials and Regulatory Milestones Shaping the RDN Market?

Clinical validation and regulatory approvals are key milestones driving confidence and adoption in the renal denervation market. Recent trials like SPYRAL HTN-OFF MED and RADIANCE-HTN SOLO have demonstrated significant and sustained reductions in systolic blood pressure with favorable safety profiles. These results have helped address early skepticism and reignited interest among cardiologists and interventional radiologists. Regulatory bodies in Europe have already approved some RDN systems, while U.S. FDA approvals are on the horizon, following promising data. Continued research into patient selection criteria, long-term outcomes, and potential synergies with pharmacological treatments is expected to accelerate adoption. These advances are also expanding RDN’s potential use in adjacent indications, such as heart failure and metabolic syndrome.

Which Market Forces and Healthcare Trends Are Driving RDN Device Demand?

The demand for renal denervation devices is rising in tandem with global hypertension prevalence, aging populations, and increasing awareness of cardiovascular risks. Healthcare providers are increasingly exploring device-based solutions to improve patient adherence and reduce the overall burden of medication management. Economic pressures and payer focus on long-term outcomes are aligning well with RDN’s promise of durable blood pressure control. Additionally, the rise in outpatient surgical centers and advancements in catheter-based procedures are making RDN more accessible and cost-effective. Patient interest in non-drug therapies - especially in regions with high treatment fatigue and polypharmacy challenges - is further accelerating interest in RDN.

The Growth in the Renal Denervation Devices Market Is Driven by Clinical Efficacy, Aging Populations, and a Shift Toward Non-Pharmacologic Interventions

The renal denervation market is expanding rapidly, fueled by several converging trends. The success of key clinical trials has established RDN as a credible alternative for patients with resistant hypertension, unlocking regulatory approvals and commercial traction. An aging global population - more prone to hypertension and cardiovascular comorbidities - is expanding the addressable market. Moreover, healthcare systems are increasingly valuing non-pharmacological interventions that offer long-term outcomes and reduced medication dependency. Procedural advancements, favorable reimbursement trends, and growing specialist adoption are further strengthening the market. Finally, patient-centric care models that prioritize lifestyle-friendly, one-time interventions are supporting a shift toward broader RDN device adoption across global health systems.

Report Scope

The report analyzes the Renal Denervation Devices market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.

Segments: Procedure Type (Percutaneous Renal Denervation, Radiofrequency Renal Denervation, Ultrasound Renal Denervation, Other Procedure Types); End-User (Hospitals, Clinics, Ambulatory Surgery Centers, Other End-Users).

Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Percutaneous Renal Denervation Devices segment, which is expected to reach US$913.1 Million by 2030 with a CAGR of a 11.3%. The Radiofrequency Renal Denervation Devices segment is also set to grow at 16.1% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, valued at $288.7 Million in 2024, and China, forecasted to grow at an impressive 17.3% CAGR to reach $463.3 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Renal Denervation Devices Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Renal Denervation Devices Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Renal Denervation Devices Market expected to evolve by 2030?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2030?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as Abbott Laboratories, Ablative Solutions, Inc., Biotronik SE & Co. KG, Boston Scientific Corporation, Cardiosonic Ltd. and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 37 companies featured in this Renal Denervation Devices market report include:

• Abbott Laboratories
• Ablative Solutions, Inc.
• Biotronik SE & Co. KG
• Boston Scientific Corporation
• Cardiosonic Ltd.
• Cordis Corporation
• Covidien PLC
• DeepQure Inc.
• Johnson & Johnson Services, Inc.
• Kona Medical, Inc.
• Medtronic PLC
• Mercator MedSystems, Inc.
• Miracor Medical SA
• Otsuka Medical Devices Co., Ltd.
• ReCor Medical, Inc.
• Renal Dynamics Ltd.
• SoniVie Ltd.
• St. Jude Medical, Inc.
• Symple Surgical, Inc.
• Terumo Corporation

Tariff Impact Analysis: Key Insights for 2025

Global tariff negotiations across 180+ countries are reshaping supply chains, costs, and competitiveness. This report reflects the latest developments as of April 2025 and incorporates forward-looking insights into the market outlook.

The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.

What's Included in This Edition:

• Tariff-adjusted market forecasts by region and segment
• Analysis of cost and supply chain implications by sourcing and trade exposure
• Strategic insights into geographic shifts

Buyers receive a free July 2025 update with:

• Finalized tariff impacts and new trade agreement effects
• Updated projections reflecting global sourcing and cost shifts
• Expanded country-specific coverage across the industry